Convalescent Plasma for COVID-19- is it Time to Say Goodbye? A Single-Center, Retrospective, Observational Study from Northern India
International Blood Research & Reviews,
Background: COVID-19 pandemic continues threatening the world with no effective treatment to tackle the menace. Till date, there is conflicting evidence on efficacy of CP in reducing COVID-19 related mortality. The objective of this study was to see disease progression and 7, 14 and 28-day mortality after CP therapy and analyze CP efficacy with/without Remdesivir.
Materials and Methods: A retrospective single-centre observational study done from August 20, 2020, to 20 November 2020. Records of 294 COVID-19 patients with moderate to severe disease given CP therapy were analysed based on disease progression and length of hospital stay, further subcategorized on age, clinical profile, risk factors, ward/ICU, ventilatory support and co-administration of Remdesivir.
Results: Lowest 7-day mortality rate was seen within age group 20-40 years (0%) and was highest in ≥61 years (24.3%). 87 patients on ventilatory support showed higher 28day mortality (48.28%) compared to non-ventilated (10.14%), (P<0.00001). Lesser 7-day mortality was seen in early CP therapy ≤3 days of admission (P=0.01). Patients requiring ICU admission showed higher 14 and 28-day mortality compared to ward P=0.001%). Median (IQR) length of hospital stay from CP transfusion was shorter, 4 (3 to 9) days in group 2 (CP only) compared to 7 (4 to 12) days in group1 (CP+Remdesivir ).
Conclusion: CP therapy in ≤3 days of hospital admission in COVID-19 patients with moderate to severe infection not on ventilatory support showed reduction in mortality and length of hospital stay. Length of hospital stay was shorter in the CP-only group as compared to the CP+ Remdesivir group.
- convalescent plasma
- CP therapy
How to Cite
Salazar E, Perez KK, Ashraf M, et al. Treatment of COVID-19 patients with convalescent plasma. Am J Pathol 2020; 190: 1680–90.
Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med 2020; 26: 1708–13.
Cantore I, Valente P. Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report. Transfus Apher Sci. 2020:102848. doi: 10.1016/j.transci.2020.102848
Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis. 2020; 222(1):38 -43.
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19.
Lancet Infect Dis, 2020;20(4):398- 400
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P; PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicenter randomized controlled trial (PLACID Trial). BMJ 2020; 371:m3939-m3939.
Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 2021;384:619-629.
RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021; published online May 14. https://doi.org/10.1016/S0140-6736(21)00897-7
Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2031893.
Salazar E, Christensen PA, Graviss EA, et al. Treatment of COVID-19 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol 2020; 190: 2290-303
Available:https://www.mohfw.gov.in/ accessed on 2nd June 2021
2020.18.03 Final G.S.R. 166(E) Amendment in Part X B & Part XII B pertains to Blood centre & blood components. https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/Accessed January12, 2020.
Recommendations for Investigational COVID-19 Convalescent Plasma, the Food and Drug Administration. [Cited 2021 March 9].
Ministry of Health & family Welfare. Clinical Management Protocol: COVID-19 version 3, dated 13/6/20
MedCalc Software Ltd. Comparison of means calculator. Available:https://www.medcalc.org/calc/comparison_of_means.php (Version 20; accessed May 22, 2021)
World Health Organization. R&D Blueprint: novel coronavirus: COVID-19 therapeutic trial synopsis. Published February 18, 2020. Accessed May 17, 2020. Available:https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf
Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021;384(7):610–8.
Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study. Nat Med. 2020;26:1708–13.
Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, et al. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med. 2020;28:357–66.
Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FP, et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv. 2020. Available:https://doi.org/10.1101/2020.07.01.20139857.
Hatzl S, Posch F, Sareban N. et al. Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. Ann. Intensive Care. 2021;11:73.
RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021; published online May 14.
Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262-1275.
DOI:10.1016/j.mayocp.2021.02.008. Epub 2021 Feb 17. PMID: 33958057; PMCID: PMC7888247.
Nicholson LB. The immune system. Essays Biochem. 2016 Oct 31;60(3):275-301.
DOI:10.1042/EBC20160017. PMID: 27784777; PMCID: PMC5091071.
Focosi D, Franchini M. COVID-19 convalescent plasma therapy: hit fast, hit hard! Vox Sang. 2021 Apr 1.
DOI:10.1111/vox.13091. Epub ahead of print. PMID: 33794556.
Shenoy AG, Hettinger AZ, Fernandez SJ, et al.Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol. 2021;192:706–713.
Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci. 2020;59(5):102875.
DOI:10.1016/j.transci.2020.102875. Epub 2020 Jul 15. PMID: 32694043; PMCID: PMC7362821.
Salazar E, Perez KK, Ashraf M, et al., Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am J Pathol. 2020;190(8):1680-1690.
Hegerova L. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood 2020;136:759–62.
Joyner MJ, Senefeld JW, Klassen SA, Mills JR, et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv [Preprint]. 2020 Aug 12:2020.08.12.20169359.
DOI:10.1101/2020.08.12.20169359. PMID: 32817978; PMCID: PMC7430623.
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:m3939.
Budhiraja S, Dewan A, Aggarwal R, Singh O, et al. Effectiveness of convalescent plasma in Indian patients with COVID-19. Blood Cells Mol Dis. 2021;88:102548.
DOI:10.1016/j.bcmd.2021.102548. Epub 2021 Feb 18. PMID: 33621948; PMCID: PMC7891064.
Tworek A, Jaroń K, Uszyńska-Kałuża B, Rydzewski A, Gil R, Deptała A, Franek E, Wójtowicz, R, Życińska K, Walecka I, Cicha M, Wierzba W, Zaczyński A, Król ZJ, Rydzewska G. Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients - propensity-score matched case-control study. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2021;105: 209–215.
Anderson J, Schauer J, Bryant S, Graves CR. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. Case Rep Womens Health. 2020;27:e00221.
DOI:10.1016/j.crwh.2020.e00221. PMID: 32426243; PMCID: PMC7229947.
Jakob Malsy, Luzia Veletzky, Janna Heide, Annette Hennigs, , et al. Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell–Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19), Clinical Infectious Diseases, 2020;ciaa 1637.
Imtiakum Jamir, Pankaj Lohia, Rajesh Kumar Pande, Rasika Setia, et al. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. Ann Hepatobiliary Pancreat Surg. 2020;24:526-532. Available:https://doi.org/10.14701/ahbps.2020.24.4.526
Das SK, Ranabhat K, Bhattarai S, Karki KB, , et al. Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID-19 patient with multimorbidity. Clin Case Rep. 2021 Feb 22;9(4):2132–7.
DOI:10.1002/ccr3.3964. Epub ahead of print. PMID: 33821192; PMCID: PMC8013972.
Koirala J, Dhimal M, Gerzoff B, Bhattarai S, et al. Treatment of COVID-19 in Hospitalized Patients with Remdesivir, Convalescent Plasma or Both in a Resource Limited Setting: A Prospective Study. SSRN Electronic Journal. 2021;10.2139/ssrn.3796911.
Cohn CS, Estcourt L, Grossman BJ, et al. COVID-19 convalescent plasma: Interim recommendations from the AABB. Transfusion. 2021 Apr; 61(4):1313-1323. DOI: 10.1111/trf.16328. Epub 2021 Mar 7. PMID: 33586160; PMCID: PMC8014606.
Abstract View: 58 times
PDF Download: 25 times